CNN (12/14, Howard) reported, “A small proportion – 14.1% – of all diagnosed cancers in the United States are detected by screening with a recommended screening test, according to a new report.” Other “diagnosed cancers tend to be found when someone has symptoms or seeks imaging or medical care for other reasons, suggests the report.” The findings were posted […]
HealthDay (11/10, Thompson) reported, “Gene editing has for the first time produced modified immune cells finely honed to target and attack cancer cells, researchers say.” The investigators “used…CRISPR to alter immune cells drawn from 16 patients who had a variety of solid cancers, including colon, breast and lung.” The findings were published in Nature and will be presented at […]
Targeted Oncology (10/14, Sava) reported, “Whether a patient with gynecologic cancer has insurance or is underinsured, there are major barriers which currently exist in accessing and affording quality care for the treatment of their cancer.” Such “disparities are a major problem as they contribute to one-third of women with gynecologic cancer never visiting a gynecologic oncologist, even […]
Cancer Network (9/30, Conroy) reported, “First-line maintenance rucaparib (Rubraca) yielded higher progression-free survival (PFS) compared with placebo among patients with newly diagnosed ovarian cancer regardless of cytoreductive surgery outcome and was favored across all subgroups, according to the results of the phase 3 ATHENA-MONO study.” These results were presented at the International Gynecologic Cancer Society 2022 […]
Cancer Therapy Advisor (9/1, Blevins Primeau) reported, “The prevalence of metastatic cancers in the United States has risen in recent years and is expected to increase further by 2025, according to a study.” The findings were published in the Journal of the National Cancer Institute. […]
Healio (8/12, Byrne) reported researchers “have developed an automated liquid biopsy test that can detect cancer DNA in the blood of patients with metastatic breast cancer within 5 hours.” The tool dubbed “Liquid Biopsy for Breast Cancer Methylation (LBx-BCM) works with a currently available molecular testing platform, GeneXpert (Cepheid), and can detect methylation in one or […]
MedPage Today (7/27, Bassett) reported, “Frequent aspirin use was associated with a decreased risk of ovarian cancer, even in the presence of risk factors, according to a…meta-analysis.” In total, “frequent aspirin use was associated with a 13% reduction in ovarian cancer risk…across 17 studies, with no difference between cohort and case-control study results…reported” researchers. Also, “risk […]
Oncology Nurse Advisor (7/19, Larson) reported that research “showed incidence of” cervical intraepithelial neoplasia grade 3 or higher “and cervical cancer is approximately 74% lower after a negative HPV screen than after a negative cytology screen in women aged 24 to 49 years.” Investigators “found that the incidence of CIN3+ at subsequent screening after a negative […]
Cancer Therapy Advisor (7/8, Dembeck) reported, “Many patients with advanced ovarian cancer may be eligible for first-line maintenance with a PARP inhibitor, according to research.” Investigators “also found that patients treated with bevacizumab and those who have BRCA mutations are likely to have better outcomes.” The findings were published in Cancer. […]
Oncology Nursing News (6/14, Fischer) reported, “Patients with ovarian cancer treated with FDA-approved PARP inhibitors had significant differences in the incidence of clinically relevant adverse events (AEs), according to results of a real-world analysis.” The findings were presented at the 2022 ASCO Annual Meeting. […]